Primary Care Focus Is Key To Bayer's Leading Position In China
Bayer Schering Pharma didn't become the number one health care company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth
You may also be interested in...
Veteran of Chinese health regulation outlines ABC's of the changes sweeping the vast nation at PharmAsia Summit.
Second Part Of Essential Drug List Will Cover More Therapeutic Areas, Says China's Minister Of Health
SHANGHAI - The second part of China's Essential Drug List, which is for mid-sized and large public hospitals, will cover more therapeutic areas, according to China's Ministry of Health
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.